6.68

2.30% 0.15

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $6.68, with a volume of 3.59M. It is up +2.30% in the last 24 hours and up +0.30% over the past month. Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$6.53

Open:

$6.55

24h Volume:

3.59M

Relative Volume:

2.39

Market Cap:

$412.50M

Revenue:

$2.00M

Net Income/Loss:

$-43.51M

P/E Ratio:

-4.9795

EPS:

-1.3415

Net Cash Flow:

$-39.73M

1W Performance:

+3.89%

1M Performance:

+0.30%

6M Performance:

+12.08%

1Y Performance:

-5.11%

1-Day Range:

$6.55

$6.855

1-Week Range:

$6.24

$6.855

52-Week Range:

$4.50

$11.41

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	6.68	412.50M	2.00M	-43.51M	-39.73M	-1.3415
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Feb-03-26	Initiated	Guggenheim	Buy
Jan-28-26	Initiated	Barclays	Equal Weight
Aug-11-25	Initiated	Wedbush	Outperform
Aug-07-25	Resumed	H.C. Wainwright	Buy
Jul-24-25	Initiated	Canaccord Genuity	Buy
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

Jun 18, 2026

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits

Jun 18, 2026

Sagimet: Buy Rating Reiterated as Denifanstat Advances and $28 Price Target Remains Unchanged - TipRanks

Jun 18, 2026